Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab versus aflibercept imaging-based efficacy study in diabetic macular edema
ChiCTR2600132727Phase 4Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of faricimab and aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Change in central retinal thickness at 6 months. Started Mar 2026; status: recruiting.
02
Drugs
faricimabaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2600132727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132727.